Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
BMC Ophthalmol ; 19(1): 195, 2019 Aug 28.
Artigo em Inglês | MEDLINE | ID: mdl-31455285

RESUMO

BACKGROUND: The subconjunctival anesthesia with local anesthetics is considered as a low-risk procedure allowing ocular surgery without serious complications typical for retro- or parabulbar anesthesia, especially in patients with preexisting Optic Nerve damage. We report development of ipsilateral transient amaurosis accompanied with mydriasis and both, direct and consensual light response absence. CASE PRESENTATION: Three patients with advanced refractory glaucoma undergoing laser cyclophotocoagulation (CPC) for intraocular pressure lowering experienced these adverse effects just few minutes after subconjunctival injection of mepivacaine 2% solution (Scandicaine® 2%, without vasoconstrictor supplementation). The vision was completely recovered to usual values in up to 20 h after mepivacaine application. Extensive ophthalmological examination, including cranial magnetic resonance imaging (MRI), revealed no further ocular abnormalities, especially no vascular constriction or thrombotic signs as well as no retinal detachment. The oculomotor function remained intact. The blockade of ipsilateral ciliary ganglion parasympathetic fibers by mepivacaine may be the responsible mechanism. Systemic pathways as drug-drug interactions seem to be unlikely involved. Importantly, all three patients tolerated the same procedure previously or at a later date without any complication. Overall, our thoroughly elaborated risk management could not determine the causative factor explaining the observed ocular complications just in the current occasion and not at other time points. CONCLUSIONS: Doctors should be aware and patients should be informed about such rare complications after subconjunctival local anesthetics administration. Adequate risk management should insure patients' safety.


Assuntos
Anestésicos Locais/efeitos adversos , Cegueira/induzido quimicamente , Túnica Conjuntiva/efeitos dos fármacos , Glaucoma de Ângulo Aberto/cirurgia , Mepivacaína/efeitos adversos , Midríase/induzido quimicamente , Distúrbios Pupilares/induzido quimicamente , Idoso , Anestesia Local/métodos , Anestésicos Locais/administração & dosagem , Cegueira/fisiopatologia , Corpo Ciliar/cirurgia , Humanos , Injeções Intraoculares , Pressão Intraocular , Fotocoagulação a Laser , Masculino , Mepivacaína/administração & dosagem , Pessoa de Meia-Idade , Midríase/fisiopatologia , Distúrbios Pupilares/fisiopatologia
2.
Amino Acids ; 47(9): 1853-63, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26066683

RESUMO

The L-arginine/nitric oxide (L-Arg/NO) pathway regulates endothelial function and may play an important role in the pathogenesis of Duchenne muscular dystrophy (DMD). Yet, this pathway is poorly investigated in children suffering from DMD. Endothelial dysfunction can affect the perfusion of contracting muscles, thus leading to ischemia and hypoxia. In the present study, we tested the hypothesis that reduced NO production due to elevated synthesis of N (G),N (G)-dimethyl-L-arginine (asymmetric dimethylarginine, ADMA), an endogenous inhibitor of NO synthesis, is a possible pathophysiological mechanism for progressive intramuscular muscle ischemia and disturbed endothelial function in children with DMD. Given the possible antagonistic action of homoarginine (hArg) on ADMA, we also analyzed this amino acid. We investigated 55 male patients with DMD and 54 healthy male controls (HC; aged 11.9 ± 4.8 vs. 11.1 ± 4.9 years, mean ± SD). Urinary creatinine and metabolites of the L-Arg/NO pathway were measured in plasma and urine by GC-MS or GC-MS/MS. Urine levels of ADMA and its major urinary metabolite dimethylamine (DMA), nitrite and nitrate (P < 0.001 for all) and hArg (P = 0.002) were significantly higher in DMD patients compared to HC, while the urinary DMA/ADMA molar ratio was lower (P = 0.002). In plasma, nitrate (P < 0.001), hArg (P = 0.002) and the hArg/ADMA ratio (P < 0.001) were lower in DMD than in HC. In plasma, ADMA (631 ± 119 vs. 595 ± 129 nM, P = 0.149), arginine and nitrite did not differ between DMD and HC. In DMD, positive correlations between ADMA, DMA or nitrate excretion and the stage of disease (according to Vignos and Thompson) were found. In DMD patients on steroid medication, lower concentrations of ADMA in plasma, and of DMA, ADMA, nitrate and hArg in urine were observed compared to non-treated patients. The L-Arg/NO pathway is impaired in DMD patients, with the disease progression being clinically negatively correlated with the extent of impairment. One of the underlying mechanisms in DMD may involve insufficient antagonism of ADMA by hArg. Steroids, but not creatine supplementation, seems to improve the L-Arg/NO pathway in DMD.


Assuntos
Arginina/análogos & derivados , Glucocorticoides/administração & dosagem , Homoarginina , Músculo Esquelético/metabolismo , Distrofia Muscular de Duchenne , Óxido Nítrico , Adolescente , Adulto , Arginina/sangue , Arginina/urina , Criança , Pré-Escolar , Estudos Transversais , Homoarginina/sangue , Homoarginina/urina , Humanos , Lactente , Masculino , Distrofia Muscular de Duchenne/sangue , Distrofia Muscular de Duchenne/tratamento farmacológico , Distrofia Muscular de Duchenne/urina , Óxido Nítrico/sangue , Óxido Nítrico/urina , Projetos Piloto
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA